MedTrace Logo

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT07262619 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-04-08

No results posted yet for this study

Summary

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

Conditions

  • Advanced Solid Tumors
  • MSI-H or dMMR Advanced Solid Tumors
  • MSI-H/dMMR Gastric Cancer
  • MSI-H/dMMR Colorectal Cancer
  • MSI-H/dMMR Gastroesophageal-junction Cancer
  • Endometrial Cancer
  • Mismatch Repair Deficient or MSI-High Solid Tumors

Interventions

DRUG

EIK1005

EIK1005 is a selective inhibitor of the Werner helicase.

DRUG

pembrolizumab (KEYTRUDA® )

Pembrolizumab is a PD-1 inhibitor.

Sponsors & Collaborators

Principal Investigators

  • Nilou Mobashery, MD · Eikon Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-20
Primary Completion
2029-03-31
Completion
2029-03-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07262619 on ClinicalTrials.gov